Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 66 entries
Sorted by: Best Match Show Resources per page
Management of adult choledochal cysts--a 15-year experience.

HPB : the official journal of the International Hepato Pancreato Biliary Association

Jesudason SR, Jesudason MR, Mukha RP, Vyas FL, Govil S, Muthusami JC.
PMID: 18333140
HPB (Oxford). 2006;8(4):299-305. doi: 10.1080/13651820500466715.

BACKGROUND: Choledochal cyst, a common surgical problem of childhood, can have a delayed presentation in adults. The clinical course in adults differs from that in children because of a higher incidence of associated hepatobiliary pathology.METHODS: The clinical data of...

Cite
Jesudason SR, Jesudason MR, Mukha RP, et al. Management of adult choledochal cysts--a 15-year experience. HPB (Oxford). 2006;8(4):299-305doi: 10.1080/13651820500466715.
Jesudason, S. R., Jesudason, M. R., Mukha, R. P., Vyas, F. L., Govil, S., & Muthusami, J. C. (2006). Management of adult choledochal cysts--a 15-year experience. HPB : the official journal of the International Hepato Pancreato Biliary Association, 8(4), 299-305. https://doi.org/10.1080/13651820500466715
Jesudason, S R Banerjee, et al. "Management of adult choledochal cysts--a 15-year experience." HPB : the official journal of the International Hepato Pancreato Biliary Association vol. 8,4 (2006): 299-305. doi: https://doi.org/10.1080/13651820500466715
Jesudason SR, Jesudason MR, Mukha RP, Vyas FL, Govil S, Muthusami JC. Management of adult choledochal cysts--a 15-year experience. HPB (Oxford). 2006;8(4):299-305. doi: 10.1080/13651820500466715. PMID: 18333140; PMCID: PMC2023900.
Copy Download .nbib Format: NLM
Heterogeneously catalyzed asymmetric hydrogenation of C=C bonds directed by surface-tethered chiral modifiers.

Journal of the American Chemical Society

Watson DJ, Jesudason RJ, Beaumont SK, Kyriakou G, Burton JW, Lambert RM.
PMID: 19754049
J Am Chem Soc. 2009 Oct 14;131(40):14584-9. doi: 10.1021/ja906356g.

Asymmetric hydrogenation of C=C bonds is of the highest importance in organic synthesis, and such reactions are currently carried out with organometallic homogeneous catalysts. Achieving heterogeneous metal-catalyzed hydrogenation, a highly desirable goal, necessitates forcing the crucial enantiodifferentiating step to...

Cite
Watson DJ, Jesudason RJ, Beaumont SK, et al. Heterogeneously catalyzed asymmetric hydrogenation of C=C bonds directed by surface-tethered chiral modifiers. J Am Chem Soc. 2009;131(40):14584-9doi: 10.1021/ja906356g.
Watson, D. J., Jesudason, R. J., Beaumont, S. K., Kyriakou, G., Burton, J. W., & Lambert, R. M. (2009). Heterogeneously catalyzed asymmetric hydrogenation of C=C bonds directed by surface-tethered chiral modifiers. Journal of the American Chemical Society, 131(40), 14584-9. https://doi.org/10.1021/ja906356g
Watson, David J, et al. "Heterogeneously catalyzed asymmetric hydrogenation of C=C bonds directed by surface-tethered chiral modifiers." Journal of the American Chemical Society vol. 131,40 (2009): 14584-9. doi: https://doi.org/10.1021/ja906356g
Watson DJ, Jesudason RJ, Beaumont SK, Kyriakou G, Burton JW, Lambert RM. Heterogeneously catalyzed asymmetric hydrogenation of C=C bonds directed by surface-tethered chiral modifiers. J Am Chem Soc. 2009 Oct 14;131(40):14584-9. doi: 10.1021/ja906356g. PMID: 19754049.
Copy Download .nbib Format: NLM
An unusual cause of subarachnoid haemorrhage in a patient with newly diagnosed neurofibromatosis: a case report.

Cases journal

Weerasinghe C, Jesudason P, Peckham D.
PMID: 19918425
Cases J. 2009 Aug 11;2:8399. doi: 10.4076/1757-1626-2-8399.

INTRODUCTION: In this report we discuss an unusual cause of subarachnoid haemorrhage in association with neurofibromatosis.CASE PRESENTATION: A previously fit 55-year-old man developed sudden onset headache with loss of consciousness. He was comatose on admission with no focal neurological...

Cite
Weerasinghe C, Jesudason P, Peckham D. An unusual cause of subarachnoid haemorrhage in a patient with newly diagnosed neurofibromatosis: a case report. Cases J. 2009;2:8399doi: 10.4076/1757-1626-2-8399.
Weerasinghe, C., Jesudason, P., & Peckham, D. (2009). An unusual cause of subarachnoid haemorrhage in a patient with newly diagnosed neurofibromatosis: a case report. Cases journal, 28399. https://doi.org/10.4076/1757-1626-2-8399
Weerasinghe, Chisha, et al. "An unusual cause of subarachnoid haemorrhage in a patient with newly diagnosed neurofibromatosis: a case report." Cases journal vol. 2 (2009): 8399. doi: https://doi.org/10.4076/1757-1626-2-8399
Weerasinghe C, Jesudason P, Peckham D. An unusual cause of subarachnoid haemorrhage in a patient with newly diagnosed neurofibromatosis: a case report. Cases J. 2009 Aug 11;2:8399. doi: 10.4076/1757-1626-2-8399. PMID: 19918425; PMCID: PMC2769435.
Copy Download .nbib Format: NLM
LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy.

Frontiers in neuroscience

Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes MM, Schober DA, Rorick-Kehn LM.
PMID: 24478625
Front Neurosci. 2014 Jan 28;8:5. doi: 10.3389/fnins.2014.00005. eCollection 2014.

We describe a novel, potent and selective orexin-2 (OX2)/hypocretin-2 receptor antagonist with in vivo activity in an animal model predictive of antidepressant-like efficacy. N-biphenyl-2-yl-4-fluoro-N-(1H-imidazol-2-ylmethyl) benzenesulfonamide HCl (LSN2424100) binds with high affinity to recombinant human OX2 receptors (Ki = 4.5...

Cite
Fitch TE, Benvenga MJ, Jesudason CD, et al. LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Front Neurosci. 2014;8:5doi: 10.3389/fnins.2014.00005.
Fitch, T. E., Benvenga, M. J., Jesudason, C. D., Zink, C., Vandergriff, A. B., Menezes, M. M., Schober, D. A., & Rorick-Kehn, L. M. (2014). LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Frontiers in neuroscience, 85. https://doi.org/10.3389/fnins.2014.00005
Fitch, Thomas E, et al. "LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy." Frontiers in neuroscience vol. 8 (2014): 5. doi: https://doi.org/10.3389/fnins.2014.00005
Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes MM, Schober DA, Rorick-Kehn LM. LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Front Neurosci. 2014 Jan 28;8:5. doi: 10.3389/fnins.2014.00005. eCollection 2014. PMID: 24478625; PMCID: PMC3904085.
Copy Download .nbib Format: NLM
Achieving universal eye health coverage: planning and human resource lessons from trachoma.

Community eye health

Courtright P, Lewallen S, Jesudason T.
PMID: 30220811
Community Eye Health. 2018;31(102):54.

No abstract available.

Cite
Courtright P, Lewallen S, Jesudason T. Achieving universal eye health coverage: planning and human resource lessons from trachoma. Community Eye Health. 2018;31(102):54
Courtright, P., Lewallen, S., & Jesudason, T. (2018). Achieving universal eye health coverage: planning and human resource lessons from trachoma. Community eye health, 31(102), 54.
Courtright, Paul, et al. "Achieving universal eye health coverage: planning and human resource lessons from trachoma." Community eye health vol. 31,102 (2018): 54.
Courtright P, Lewallen S, Jesudason T. Achieving universal eye health coverage: planning and human resource lessons from trachoma. Community Eye Health. 2018;31(102):54. PMID: 30220811; PMCID: PMC6134455.
Copy Download .nbib Format: NLM
Type VI Choledochal Cysts-Case Report and Review of Literature.

Surgery journal (New York, N.Y.)

Amarjothi JMV, Ramasamy V, Jesudasan J, NaganathBabu OL.
PMID: 31453343
Surg J (N Y). 2019 Aug 23;5(3):e82-e86. doi: 10.1055/s-0039-1693652. eCollection 2019 Jul.

Choledochal cysts (CDC), are rare congenital dilations involving the extra hepatic biliary apparatus with or without dilation of the intrahepatic bile ducts. They are conventionally classified into five types. A new type, type VI, causing dilation of the cystic...

Cite
Amarjothi JMV, Ramasamy V, Jesudasan J, et al. Type VI Choledochal Cysts-Case Report and Review of Literature. Surg J (N Y). 2019;5(3):e82-e86doi: 10.1055/s-0039-1693652.
Amarjothi, J. M. V., Ramasamy, V., Jesudasan, J., & NaganathBabu, O. L. (2019). Type VI Choledochal Cysts-Case Report and Review of Literature. Surgery journal (New York, N.Y.), 5(3), e82-e86. https://doi.org/10.1055/s-0039-1693652
Amarjothi, J M V, et al. "Type VI Choledochal Cysts-Case Report and Review of Literature." Surgery journal (New York, N.Y.) vol. 5,3 (2019): e82-e86. doi: https://doi.org/10.1055/s-0039-1693652
Amarjothi JMV, Ramasamy V, Jesudasan J, NaganathBabu OL. Type VI Choledochal Cysts-Case Report and Review of Literature. Surg J (N Y). 2019 Aug 23;5(3):e82-e86. doi: 10.1055/s-0039-1693652. eCollection 2019 Jul. PMID: 31453343; PMCID: PMC6707803.
Copy Download .nbib Format: NLM
SERCA directs cell migration and branching across species and germ layers.

Biology open

Bower DV, Lansdale N, Navarro S, Truong TV, Bower DJ, Featherstone NC, Connell MG, Al Alam D, Frey MR, Trinh LA, Fernandez GE, Warburton D, Fraser SE, Bennett D, Jesudason EC.
PMID: 28821490
Biol Open. 2017 Oct 15;6(10):1458-1471. doi: 10.1242/bio.026039.

Branching morphogenesis underlies organogenesis in vertebrates and invertebrates, yet is incompletely understood. Here, we show that the sarco-endoplasmic reticulum Ca

Cite
Bower DV, Lansdale N, Navarro S, et al. SERCA directs cell migration and branching across species and germ layers. Biol Open. 2017;6(10):1458-1471doi: 10.1242/bio.026039.
Bower, D. V., Lansdale, N., Navarro, S., Truong, T. V., Bower, D. J., Featherstone, N. C., Connell, M. G., Al Alam, D., Frey, M. R., Trinh, L. A., Fernandez, G. E., Warburton, D., Fraser, S. E., Bennett, D., & Jesudason, E. C. (2017). SERCA directs cell migration and branching across species and germ layers. Biology open, 6(10), 1458-1471. https://doi.org/10.1242/bio.026039
Bower, Danielle V, et al. "SERCA directs cell migration and branching across species and germ layers." Biology open vol. 6,10 (2017): 1458-1471. doi: https://doi.org/10.1242/bio.026039
Bower DV, Lansdale N, Navarro S, Truong TV, Bower DJ, Featherstone NC, Connell MG, Al Alam D, Frey MR, Trinh LA, Fernandez GE, Warburton D, Fraser SE, Bennett D, Jesudason EC. SERCA directs cell migration and branching across species and germ layers. Biol Open. 2017 Oct 15;6(10):1458-1471. doi: 10.1242/bio.026039. PMID: 28821490; PMCID: PMC5665464.
Copy Download .nbib Format: NLM
Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease.

Case reports in nephrology

Jalleh R, Basu G, Le Leu R, Jesudason S.
PMID: 30519493
Case Rep Nephrol. 2018 Nov 04;2018:7384763. doi: 10.1155/2018/7384763. eCollection 2018.

BACKGROUND: Hypocalcaemia is increasingly recognized as a complication of denosumab use in Chronic Kidney Disease (CKD) patients with osteoporosis. Despite Therapeutic Goods Administration (TGA) notifications in 2013, we have subsequently encountered several cases of denosumab-induced hypocalcaemia, raising concern about...

Cite
Jalleh R, Basu G, Le Leu R, et al. Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease. Case Rep Nephrol. 2018;2018:7384763doi: 10.1155/2018/7384763.
Jalleh, R., Basu, G., Le Leu, R., & Jesudason, S. (2018). Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease. Case reports in nephrology, 20187384763. https://doi.org/10.1155/2018/7384763
Jalleh, Ryan, et al. "Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease." Case reports in nephrology vol. 2018 (2018): 7384763. doi: https://doi.org/10.1155/2018/7384763
Jalleh R, Basu G, Le Leu R, Jesudason S. Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease. Case Rep Nephrol. 2018 Nov 04;2018:7384763. doi: 10.1155/2018/7384763. eCollection 2018. PMID: 30519493; PMCID: PMC6241374.
Copy Download .nbib Format: NLM
Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges.

International journal of women's health

McBride L, Wilkinson C, Jesudason S.
PMID: 32547249
Int J Womens Health. 2020 May 25;12:409-422. doi: 10.2147/IJWH.S204997. eCollection 2020.

Autosomal dominant polycystic kidney disease (ADPKD) affects up to 1 in 1000 people. The disease is characterized by the progressive development of cysts throughout the renal parenchyma due to inherited pathogenic variants in genes including

Cite
McBride L, Wilkinson C, Jesudason S. Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges. Int J Womens Health. 2020;12:409-422doi: 10.2147/IJWH.S204997.
McBride, L., Wilkinson, C., & Jesudason, S. (2020). Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges. International journal of women's health, 12409-422. https://doi.org/10.2147/IJWH.S204997
McBride, Lucy, et al. "Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges." International journal of women's health vol. 12 (2020): 409-422. doi: https://doi.org/10.2147/IJWH.S204997
McBride L, Wilkinson C, Jesudason S. Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges. Int J Womens Health. 2020 May 25;12:409-422. doi: 10.2147/IJWH.S204997. eCollection 2020. PMID: 32547249; PMCID: PMC7261500.
Copy Download .nbib Format: NLM
Risperidone for successful treatment of postictal psychosis refractory to olanzapine.

Proceedings (Baylor University. Medical Center)

Park AK, Jesudasen SJ, Olson KR.
PMID: 33678978
Proc (Bayl Univ Med Cent). 2021 Jan 20;34(2):318-320. doi: 10.1080/08998280.2020.1860450.

Postictal psychosis (PIP) in patients with epilepsy is often mistaken for other primary psychiatric disorders. Depending on its severity, PIP often prompts empiric treatment with atypical antipsychotics, which are balanced against the risk of lowered seizure thresholds. Here we...

Cite
Park AK, Jesudasen SJ, Olson KR. Risperidone for successful treatment of postictal psychosis refractory to olanzapine. Proc (Bayl Univ Med Cent). 2021;34(2):318-320doi: 10.1080/08998280.2020.1860450.
Park, A. K., Jesudasen, S. J., & Olson, K. R. (2021). Risperidone for successful treatment of postictal psychosis refractory to olanzapine. Proceedings (Baylor University. Medical Center), 34(2), 318-320. https://doi.org/10.1080/08998280.2020.1860450
Park, Albert K, et al. "Risperidone for successful treatment of postictal psychosis refractory to olanzapine." Proceedings (Baylor University. Medical Center) vol. 34,2 (2021): 318-320. doi: https://doi.org/10.1080/08998280.2020.1860450
Park AK, Jesudasen SJ, Olson KR. Risperidone for successful treatment of postictal psychosis refractory to olanzapine. Proc (Bayl Univ Med Cent). 2021 Jan 20;34(2):318-320. doi: 10.1080/08998280.2020.1860450. PMID: 33678978; PMCID: PMC7901375.
Copy Download .nbib Format: NLM
Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity.

ACS medicinal chemistry letters

Jesudason CD, Baker JE, Bryant RD, Fisher JW, O'Farrell LS, Gaich GA, He MM, Kahl SD, Kriauciunas AV, Heiman ML, Peters MA, Rito CJ, Satterwhite JH, Tinsley FC, Trankle WG, Shuker AJ.
PMID: 24900353
ACS Med Chem Lett. 2011 May 23;2(8):583-6. doi: 10.1021/ml200071k. eCollection 2011 Aug 11.

We report the novel combination of a selective beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor (sibutramine) with potential for the treatment of obesity. The synthesis and characterization of 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide (LY377604), a human β3-adrenergic receptor agonist and β1- and...

Cite
Jesudason CD, Baker JE, Bryant RD, et al. Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity. ACS Med Chem Lett. 2011;2(8):583-6doi: 10.1021/ml200071k.
Jesudason, C. D., Baker, J. E., Bryant, R. D., Fisher, J. W., O'Farrell, L. S., Gaich, G. A., He, M. M., Kahl, S. D., Kriauciunas, A. V., Heiman, M. L., Peters, M. A., Rito, C. J., Satterwhite, J. H., Tinsley, F. C., Trankle, W. G., & Shuker, A. J. (2011). Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity. ACS medicinal chemistry letters, 2(8), 583-6. https://doi.org/10.1021/ml200071k
Jesudason, Cynthia D, et al. "Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity." ACS medicinal chemistry letters vol. 2,8 (2011): 583-6. doi: https://doi.org/10.1021/ml200071k
Jesudason CD, Baker JE, Bryant RD, Fisher JW, O'Farrell LS, Gaich GA, He MM, Kahl SD, Kriauciunas AV, Heiman ML, Peters MA, Rito CJ, Satterwhite JH, Tinsley FC, Trankle WG, Shuker AJ. Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity. ACS Med Chem Lett. 2011 May 23;2(8):583-6. doi: 10.1021/ml200071k. eCollection 2011 Aug 11. PMID: 24900353; PMCID: PMC4018109.
Copy Download .nbib Format: NLM
Making gains sustainable: partnering with WASH to stop the transmission of trachoma.

Community eye health

Wohlgemuth L, Hamilton H, Jesudason T.
PMID: 29915467
Community Eye Health. 2018;31(101):24.

No abstract available.

Cite
Wohlgemuth L, Hamilton H, Jesudason T. Making gains sustainable: partnering with WASH to stop the transmission of trachoma. Community Eye Health. 2018;31(101):24
Wohlgemuth, L., Hamilton, H., & Jesudason, T. (2018). Making gains sustainable: partnering with WASH to stop the transmission of trachoma. Community eye health, 31(101), 24.
Wohlgemuth, Leah, et al. "Making gains sustainable: partnering with WASH to stop the transmission of trachoma." Community eye health vol. 31,101 (2018): 24.
Wohlgemuth L, Hamilton H, Jesudason T. Making gains sustainable: partnering with WASH to stop the transmission of trachoma. Community Eye Health. 2018;31(101):24. PMID: 29915467; PMCID: PMC5998399.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 66 entries